ClinicalTrials.gg
RecruitingNCT06948487Updated Jul 17, 2025

Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

An observational study in Gastritis, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
12,000
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.

Started
2025
the only one that year
Observational
7 of 32
2 open now
Registered
30th of 32
by date
Lead sponsor
5 of 32
Daewoong Pharmaceutical Co. LTD.

Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the only one that started in 2025, is one of 7 observational ones, and was the 30th registered.

Gastritis

136 studies on the registry are indexed under Gastritis; 24 are open to participants now.

Browse Gastritis studies →

Open to participants now

3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gastritis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.

Read the detailed description

In this observational study, patient-reported data will be collected using an electronic application (e-PRO). The survey on subjective symptoms will be administered twice-once before and once after the administration of Fexuclue tablets. Additionally, a survey on medication convenience will be conducted once at 2 weeks (up to a maximum of 4 weeks) post-administration.

At the same time point (2 to 4 weeks after administration), patients will self-assess their overall improvement through the e-PRO application. Investigators will also evaluate final improvement based on clinical judgment in a real-world setting and record the outcome in the Case Report Form (CRF).

03

Conditions studied

  • Gastritis

Keywords

  • Acute
  • Chronic
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The proportion of subjects with improved subjective symptoms at 2 to 4 weeks after Fexuclue tablet administration for gastritis will be assessed based on patient-reported outcomes. Referring to prior Phase 3 data, a 60% efficacy rate is assumed. Using G-Power 3.1.9.7 with a two-sided significance level of 0.05 and statistical power of 95%, the minimum sample size was calculated to be 10,434. Considering a 25% dropout rate, approximately 13,000 participants will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects between the ages of 19 and 75 years at the time of obtaining written .
  • Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
  • Subjects who present with at least one subjective symptom requiring medical treatment
  • Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.

Exclusion criteria

Exclusion Criteria:

  • Individuals who fall under any for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
  • Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fexuclue® Tab

    Fexuclue® Tab Fexuclue® Tab Fexuprazan Hydrochloride 10mg

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with improvement in subjective symptoms

    The proportion of subjects with improvement in subjective symptoms at Week 2 (up to Week 4) compared to baseline.

    Time frame: 2 weeks(up to 4 weeks)

Secondary outcomes

  1. Change from baseline in the mean frequency scores of individual subjective symptoms assessed at each time point using a 5-point scale ranging from 0 (not at all) to 4 (daily)

    Change from baseline in the mean frequency scores of individual subjective symptoms assessed at each time point using a 5-point scale ranging from 0 (not at all) to 4 (daily) at 2 weeks(up to 4 weeks)

    Time frame: 2 weeks(up to 4 weeks)

  2. Change from baseline in the mean severity scores of individual subjective symptoms assessed at each time point using a 5-point scale ranging from 0 (not at all) to 4 (very severe)

    Change from baseline in the mean severity scores of individual subjective symptoms assessed at each time point using a 5-point scale ranging from 0 (not at all) to 4 (very severe) at 2 weeks(up to 4 weeks)

    Time frame: 2 weeks(up to 4 weeks)

  3. Disappearance rate of subjective symptoms

    Disappearance rate of subjective symptoms at 2 weeks(up to 4 weeks)

    Time frame: 2 weeks(up to 4 weeks)

  4. Overall improvement assessed at each time point by both the subject and the investigator using the Final Improvement Assessment, which consists of a 5-point scale ranging from 'fully recovered' to 'worsened'

    Overall improvement assessed at each time point by both the subject and the investigator using the Final Improvement Assessment, which consists of a 5-point scale ranging from 'fully recovered' to 'worsened' at 2 weeks(up to 4 weeks)

    Time frame: 2 weeks(up to 4 weeks)

  5. Patient-reported satisfaction with medication intake convenience assessed at Week 2 (up to Week 4) compared to baseline, using a 5-point scale ranging from 'very convenient' to 'very inconvenient'

    Patient-reported satisfaction with medication intake convenience assessed at Week 2 (up to Week 4) compared to baseline, using a 5-point scale ranging from 'very convenient' to 'very inconvenient' at 2 weeks(up to 4 weeks)

    Time frame: 2 weeks(up to 4 weeks)

07

Study locations

1 of 1 sites recruiting
  • Masong Kim Internal Medicine Clinic
    Seoul, South Korea
    Recruiting
    • Jingun Kim · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 29, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Jun 3, 2027
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06948487
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Jun 17, 2025
Primary completion
Nov 30, 2025 (estimated)
Completion
Jun 3, 2027 (estimated)
Last update
Jul 17, 2025

Study contacts

So Heui Kim
Contact
2210325@daewoong.co.kr
82-10-2994-5887
Jingun Kim, Dr.
principal investigator · Masong Kim Internal Medicine Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion